Asundexian (BAY2433334)
Sponsors
Bayer
Conditions
Acute Myocardial InfarctionAcute Non-cardioembolic Ischemic StrokeAtrial FibrillationHepatic ImpairmentHigh-risk Transient Ischemic AttackNon-cardioembolic Ischemic StrokePrevention of Ischemic StrokePrevention of Stroke or Systemic Embolism
Phase 1
Phase 3
A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke
TerminatedNCT05643573
Start: 2022-12-05End: 2024-01-31Updated: 2024-12-09
A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke
CompletedNCT05686070
Start: 2023-01-26End: 2025-10-23Updated: 2025-11-12